Bailard, Inc. Cyma Bay Therapeutics, Inc. Transaction History

Bailard, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 25, 2022	SELL	$2.77 - $3.64 $37,949 - $49,868	-13,700 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$3.23 - $4.6 $44,251 - $63,019	13,700 New	13,700 $46,000
Q4 2019 Jan 31, 2020	SELL	$1.33 - $5.93 $410,571 - $1.83 Million	-308,700 Closed	0 $0
Q2 2019 Jul 26, 2019	BUY	$6.05 - $13.66 $566,280 - $1.28 Million	93,600 Added 43.51%	308,700 $2.21 Million
Q1 2019 Apr 24, 2019	BUY	$8.16 - $13.42 $735,216 - $1.21 Million	90,100 Added 72.08%	215,100 $2.86 Million

Q4 2018 Feb 05, 2019	BUY	$6.54 - $11.74 $817,500 - $1.47 Million	125,000 New	125,000 $984,000

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.